Suppr超能文献

辽宁成大公司生产的纯化Vero细胞狂犬病疫苗(PVRV)在50岁及以上中国成年人中按照萨格勒布2-1-1或5剂埃森方案接种后的免疫原性和安全性。

Immunogenicity and safety of purified vero cell rabies vaccine (PVRV) produced by Liaoning Cheng Da Co. under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese adults aged 50 and above.

作者信息

Wang Jing, Luo FengJi, Feng ZiJian, Li Li, Bai YunHua, Ai Xing, Ma JianXin, Zhang Zheng, Shi NianMin

机构信息

a ChaoYang Center for Disease Prevention and Control , Beijing , China.

b China Center for Disease Prevention and Control ; Beijing , China.

出版信息

Hum Vaccin Immunother. 2017 Jan 2;13(1):144-150. doi: 10.1080/21645515.2016.1230260.

Abstract

BACKGROUND

Two kinds of regimens (2-1-1 and 1-1-1-1-1) can be selected after Zagreb regimen(2-1-1)of PVRV was officially approved in Beijing in January 2015. Up to now, the subjects for most studies about the comparison between Zagreb and Essen regimen are under 50 y old, rarely at and above. Aging of the immune system may result in decreasing efficacy of vaccination, especially for adults aged above 65-70 y. This study compared the safety and immunogenicity of the Zagreb and Essen regimen in Chinese adults aged 50 and above with the goal to provide a supplemental data for this age group.

METHODS

A total of 114 cases were divided into 2 groups randomly, received PVRV under the Zagreb and Essen regimens respectively. Serum samples were collected at D0, D7, D14, D42, D180 and D365 to determine the rabies serum neutralizing antibody by rapid fluorescent focus inhibition test (RFFIT). Safety analyses were made by comparing the AEs in day-3, day-7, and day-(7 + 21) in Zagreb or day-(7 + 28) in Essen by gender and age cohorts.

RESULTS

617 blood samples were obtained. Two groups showed similar immunogenicity, the neutralizing antibody titer of all subjects at D14 and D42 showed >0.5 IU/ml. Under the same regimen, Subjects ≥65 y had lower GMC than those who <65 years from D7 to D365 within 2 groups. This difference was significantly shown on D7, D14, D180 in Zagreb group, and on D180 in Essen group (t = 2.38, p = 0.02; t = 3.78, p < 0.001; t = 2.30, p = 0.03; t = 4.42, p < 0.001). Subjects<65 years had higher seroconversion rate compared to ≥65 y on D7, D180 and D365 in both 2 groups, this difference was also significantly shown on D180, D365 in Zagreb group and on D180 in Essen group (χ = 20.66, p < 0.001; χ = 6.56, p = 0.02; χ = 10.96, p = 0.002). Two regimens all showed favorable performances with mildly or common adverse events (AEs). The incidence of local AEs after 3 d in Essen group was higher than Zagreb group (χ = 9.69, p = 0.002). The most common local AE was pain, the incidences (8.8%) in Zagreb group was higher than Essen group (8.4%, χ = 5.12, p = 0.02). All AEs for Zagreb group and 52.3% of AEs for Essen group occurred during the first 72 hours. During the first 72 hours, subjects aged <65 in Zagreb group (16.26%) had higher incidences of AEs than Essen group (8.57%, χ = 4.54, p = 0.03), males in Zagreb group (16.05%) had higher incidence of AEs than Essen group (5.71%, χ = 5.34, p = 0.02). The incidences of AEs close in during the first 7 d.

CONCLUSION

The Zagreb and Essen regimens demonstrated the similar safety and efficacy of PVRV in Chinese adults aged 50 and above. People ≥65 y showed reduced immune response to both regimens. More AEs for the Zagreb regimen were observed within the first 72 hours, especially for male and people < 65 y.

摘要

背景

2015年1月,北京正式批准采用萨格勒布方案(2-1-1)后,可选择两种方案(2-1-1和1-1-1-1-1)。到目前为止,大多数关于萨格勒布方案和埃森方案比较的研究对象年龄在50岁以下,很少有50岁及以上的。免疫系统衰老可能导致疫苗接种效果下降,尤其是65 - 70岁及以上的成年人。本研究比较了萨格勒布方案和埃森方案在中国50岁及以上成年人中的安全性和免疫原性,旨在为该年龄组提供补充数据。

方法

共114例患者随机分为2组,分别接受萨格勒布方案和埃森方案的人用狂犬病疫苗(PVRV)接种。在第0、7、14、42、180和365天采集血清样本,通过快速荧光灶抑制试验(RFFIT)检测狂犬病血清中和抗体。通过比较萨格勒布方案第3、7天和第(7 + 21)天或埃森方案第(7 + 28)天按性别和年龄队列划分的不良事件(AE)进行安全性分析。

结果

共获得617份血样。两组免疫原性相似,所有受试者在第14天和第42天的中和抗体滴度均>0.5 IU/ml。在相同方案下,两组中≥65岁的受试者在第7天至第365天的几何平均浓度(GMC)低于<65岁的受试者。这种差异在萨格勒布组的第7、14、180天以及埃森组的第180天有显著表现(t = 2.38,p = 0.02;t = 3.78,p < 0.001;t = 2.30,p = 0.03;t = 4.42,p < 0.001)。在第7、180和365天,两组中<65岁的受试者血清转化率均高于≥65岁的受试者,这种差异在萨格勒布组的第180、365天以及埃森组的第180天也有显著表现(χ = 20.66,p < 0.001;χ = 6.56,p = 0.02;χ = 10.96,p = 0.002)。两种方案的不良事件均表现为轻度或常见。埃森组接种3天后局部AE的发生率高于萨格勒布组(χ = 9.69,p = 0.002)。最常见的局部AE是疼痛,萨格勒布组的发生率(8.8%)高于埃森组(8.4%,χ = 5.12,p = 0.02)。萨格勒布组的所有AE和埃森组52.3%的AE发生在最初72小时内。在最初72小时内,萨格勒布组<65岁的受试者AE发生率(16.26%)高于埃森组(8.57%,χ = 4.54,p = 0.03),萨格勒布组男性AE发生率(16.05%)高于埃森组(5.71%,χ = 5.34,p = 0.02)。第1周内AE发生率相近。

结论

萨格勒布方案和埃森方案在50岁及以上中国成年人中显示出相似的人用狂犬病疫苗安全性和有效性。≥65岁的人群对两种方案的免疫反应均降低。萨格勒布方案在最初72小时内观察到更多AE,尤其是男性和<65岁的人群。

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验